Novavax (NASDAQ: NVAX) lags behind bigger players in the COVID-19 vaccine arena such as Pfizer and Moderna. However, in late January the biotech announced very promising results from a late-stage study of its experimental coronavirus vaccine. In this Motley Fool Live video recorded on Feb. 1, “The Wrap” host Jason Hall and Fool.com writer Keith Speights discuss why Novavax’s COVID-19 vaccine results were so stellar.
Why Novavax’s COVID Vaccine Results Were So Stellar
Latest from Blog
Image source: The Motley Fool. Broadcom Ltd (NASDAQ: AVGO)Q1 2021 Earnings CallMar 04, 2021, 5:00 p.m. ET Operator…
Image source: The Motley Fool. Great Panther Silver Ltd. (NYSEMKT: GPL)Q4 2020 Earnings CallMar 04, 2021, 12:00 p.m.…
Image source: The Motley Fool. Smith & Wesson Brands, Inc. (NASDAQ: SWBI)Q3 2021 Earnings CallMar 04, 2021, 5:00…
Image source: The Motley Fool. Chiasma (NASDAQ: CHMA)Q4 2020 Earnings CallMar 04, 2021, 5:00 p.m. ET Operator Continue…
The stock market has changed gears in the past few weeks. The high-growth stocks that led…